Wang JL, Sun YL, Kang Z, Zhang SK, Yu CX, Zhang W, Xie H, Lin HL. Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report. World J Clin Cases 2023; 11(22): 5309-5315 [PMID: 37621578 DOI: 10.12998/wjcc.v11.i22.5309]
Corresponding Author of This Article
Hong-Li Lin, PhD, Chief Physician, Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116000, Liaoning Province, China. linhongli1216@163.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Wang JL, Sun YL, Kang Z, Zhang SK, Yu CX, Zhang W, Xie H, Lin HL. Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report. World J Clin Cases 2023; 11(22): 5309-5315 [PMID: 37621578 DOI: 10.12998/wjcc.v11.i22.5309]
World J Clin Cases. Aug 6, 2023; 11(22): 5309-5315 Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5309
Anti-phospholipase A2 receptor-associated membranous nephropathy with human immunodeficiency virus infection treated with telitacicept: A case report
Jin-Ling Wang, Yan-Ling Sun, Zhe Kang, Sheng-Kun Zhang, Chun-Xin Yu, Wan Zhang, Hua Xie, Hong-Li Lin
Jin-Ling Wang, Yan-Ling Sun, Zhe Kang, Sheng-Kun Zhang, Chun-Xin Yu, Wan Zhang, Hua Xie, Department of Nephrology, Dalian Renal Care Hospital, Dalian 116000, Liaoning Province, China
Hong-Li Lin, Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian 116000, Liaoning Province, China
Author contributions: Wang JL, Sun YL, Kang Z, Zhang SK, Yu CX, Zhang W, and Xie H participated in the acquisition of clinical data; Lin HL, Wang JL, Sun YL, and Xie H carried out analysis of patient’s clinical course and data interpretation; Wang JL and Lin HL wrote a draft of the manuscript; Sun YL and Kang Z prepared figures; Zhang SK, Yu CX, Zhang W, and Xie H revised it critically; All authors read and approved the final manuscript.
Informed consent statement: The informed consent form was signed by patient.
Conflict-of-interest statement: The authors declare that there were no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hong-Li Lin, PhD, Chief Physician, Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116000, Liaoning Province, China. linhongli1216@163.com
Received: March 2, 2023 Peer-review started: March 2, 2023 First decision: June 12, 2023 Revised: July 7, 2023 Accepted: July 17, 2023 Article in press: July 17, 2023 Published online: August 6, 2023 Processing time: 153 Days and 20.4 Hours
Abstract
BACKGROUND
The co-occurrence of Anti-phospholipase A2 receptor-associated membranous nephropathy (anti-PLA2R-MN) and human immunodeficiency virus (HIV) infection is a rare clinical scenario, presenting significant challenges in terms of management and treatment.
CASE SUMMARY
A 32-year-old Chinese male diagnosed with HIV infection presented with a clinical history of proteinuria persisting for over two years. A kidney biopsy demonstrated subepithelial immune complex deposition and a thickened glomerular basement membrane, indicative of stage I-II membranous nephropathy. Immunofluorescence staining revealed granular deposition of PLA2R (3+) along the glomerular capillary loops, corroborated by a strongly positive anti-PLA2R antibody test (1:320). Initial treatment involving losartan potassium, rivaroxaban, tacrolimus, and rituximab was discontinued due to either poor effectiveness or the occurrence of adverse events. Following a regimen of weekly subcutaneous injections of telitacicept (160 mg), a marked decline in the 24 h urine protein was observed within a three-month period, accompanied by a rise in serum albumin level. No significant reductions in peripheral blood CD3+CD4+T and CD3+CD8+T cell counts were detected. The patient's physical and psychological conditions showed significant improvements, with no adverse events reported during the treatment course.
CONCLUSION
Telitacicept might offer a potential therapeutic avenue for patients diagnosed with anti-PLA2R-MN concomitant with HIV infection.
Core Tip: The clinical management of anti-phospholipase A2 receptor-associated membranous nephropathy concurrent with human immunodeficiency virus infection presents significant challenges, primarily due to potential unregulated immune responses. In this report, we demonstrated that a weekly subcutaneous injection of telitacicept (160 mg) could ameliorate the 24-h urinary protein levels and enhance serum albumin concentrations, with no discernible impact on T cell counts, showcasing its safety profile.
